Updates on the antinociceptive mechanism hypothesis of botulinum toxin A

Van Den, 1990, Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: the clinical usefulness of botulinum toxin-A in treating neurologic disorders, Neurology, 40, 1332, 10.1212/WNL.40.9.1332

Aoki, 2004, Botulinum toxin: a successful therapeutic protein, Curr Med Chem, 11, 3085, 10.2174/0929867043363802

Tsui, 1986, Double-blind study of botulinum toxin in spasmodic torticollis, Lancet, 2, 245, 10.1016/S0140-6736(86)92070-2

Brin, 1987, Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm, Mov Disord, 2, 237, 10.1002/mds.870020402

Binder, 2000, Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study, Otolaryngol Head Neck Surg, 123, 669, 10.1067/mhn.2000.110960

Diener, 2010, OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial, Cephalalgia, 30, 804, 10.1177/0333102410364677

Aurora, 2010, OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial, Cephalalgia, 30, 793, 10.1177/0333102410364676

Dodick, 2010, OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program, Headache, 50, 921, 10.1111/j.1526-4610.2010.01678.x

Schoenen, 2010, Botulinum toxin in headache treatment: finally a promising path?, Cephalalgia, 30, 771, 10.1177/0333102410373154

Rosetto, 2004, Different mechanism of blockade of neurotoxins by presynaptic neurotoxins, Toxicol Lett, 149, 91, 10.1016/j.toxlet.2003.12.023

Dolly, 2006, The structure and mode of action of different botulinum toxins, Eur J Neurol, 13, 1, 10.1111/j.1468-1331.2006.01648.x

Aoki, 2005, Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A, Neurotoxicology, 26, 785, 10.1016/j.neuro.2005.01.017

Aoki, 2003, Evidence for antinociceptive activity of botulinum toxin type A in pain management, Headache, 43, S9, 10.1046/j.1526-4610.43.7s.3.x

Woolf, 2001, Mechanism-based pain diagnosis: issues for analgesic drug development, Anesthesiology, 95, 241, 10.1097/00000542-200107000-00034

Woolf, 2000, Neuronal plasticity: increasing the gain in pain, Science, 288, 1765, 10.1126/science.288.5472.1765

Woolf, 2006, Plasticity and pain: role of the dorsal horn, 91

Woolf, 2004, Pain: moving from symptom control toward mechanism-specific pharmacologic management, Ann Intern Med, 140, 441, 10.7326/0003-4819-140-8-200404200-00010

Morenilla-Palao, 2004, Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity, J Biol Chem, 279, 25665, 10.1074/jbc.M311515200

Planells-Cases, 2005, Functional aspects and mechanisms of TRPV1 involvement in neurogenic inflammation that leads to thermal hyperalgesia, Pflugers Arch, 451, 151, 10.1007/s00424-005-1423-5

Tominaga, 2004, Thermosensation and pain, J Neurobiol, 61, 3, 10.1002/neu.20079

Goadsby, 2009, Neurobiology of migraine, Neuroscience, 161, 327, 10.1016/j.neuroscience.2009.03.019

Burstein, 2000, An association between migraine and cutaneous allodynia, Ann Neurol, 47, 614, 10.1002/1531-8249(200005)47:5<614::AID-ANA9>3.0.CO;2-N

Burstein, 2000, The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine, Brain, 123, 1703, 10.1093/brain/123.8.1703

Burstein, 2004, Defeating migraine pain with triptans: a race against the development of cutaneous allodynia, Ann Neurol, 55, 19, 10.1002/ana.10786

Diener, 2011, Treatment of chronic migraine, Curr Pain Headache Rep, 15, 64, 10.1007/s11916-010-0159-x

Pavone, 2010, Botulinum neurotoxin for pain management: insights from animal models, Toxins, 2, 2890, 10.3390/toxins2122890

Cui, 2004, Subcutaneous administration of botulinum toxin A reduces formalin-induced pain, Pain, 107, 125, 10.1016/j.pain.2003.10.008

Abbadie, 1997, Differential contribution of the two phases of the formalin test to the pattern of c-fos expression in the rat spinal cord: studies with remifentanil and lidocaine, Pain, 69, 101, 10.1016/S0304-3959(96)03285-X

Dickenson, 1987, Subcutaneous formalin-induced activity of dorsal horn neurones in the rat: differential response to an intrathecal opiate administered pre or post formalin, Pain, 30, 349, 10.1016/0304-3959(87)90023-6

Kaneko, 2000, Intrathecally administered gabapentin inhibits formalin-evoked nociception and the expression of Fos-like immunoreactivity in the spinal cord of the rat, J Pharmacol Exp Ther, 292, 743

Abbadie, 1997, Inflammation increases the distribution of dorsal horn neurons that internalize the neurokinin-1 receptor in response to noxious and non-noxious stimulation, J Neurosci, 17, 8049, 10.1523/JNEUROSCI.17-20-08049.1997

Coderre, 1990, Central nervous system plasticity in the tonic pain response to subcutaneous formalin injection, Brain Res, 535, 155, 10.1016/0006-8993(90)91835-5

Taylor, 1995, Persistent cardiovascular and behavioral nociceptive responses to subcutaneous formalin require peripheral nerve input, J Neurosci, 15, 7575, 10.1523/JNEUROSCI.15-11-07575.1995

Dickenson, 1987, Peripheral origins and central modulation of subcutaneous formalin-induced activity of rat dorsal horn neurones, Neurosci Lett, 83, 207, 10.1016/0304-3940(87)90242-4

Cui, 2004, 158

Francis J, You S [AGN], Satorius A, Ardila C, Brown M, Li Z, et al. Analgesic properties and mechanism of action of botulinum toxin type A (BOTOX(R)). Neurotox Res 2006 Apr; 9(2-3):229. ABS-P19.

Cui M, Li Z, Khanijou S [AGN], Rubino J, You S [AGN], Aoki R, et al. Subcutaneous administration of BOTOX(R) inhibits capsaicin-induced thermal hyperalgesia and expansion of horn neuronal receptive field area. Soc Neurosci Abstr Viewer Itiner, program, 2003.

Chuang, 2004, Intravesical botulinum toxin A administration produces analgesia against acetic acid induced bladder pain responses in rats, J Urol, 172, 1529

Apostolidis, 2005, Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity, J Urol, 174, 977

Birder, 2001, Vanilloid receptor expression suggests a sensory role for urinary bladder epithelial cells, Proc Natl Acad Sci U S A, 98, 13396, 10.1073/pnas.231243698

Barrick, 2005, Regulation of chemical and mechanical-evoked ATP release from urinary bladder urothelium by botulinum toxin type A, Toxins Meeting [Online], ABS-5

Apostolidis, 2006, Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity, Eur Urol, 49, 644, 10.1016/j.eururo.2005.12.010

Kramer, 2003, Botulinum toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin, J Neurol, 250, 188

Voller, 2003, A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A, Neurology, 61, 940, 10.1212/01.WNL.0000086374.92906.6A

Blersch, 2002, Botulinum toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebo-controlled, randomized study, J Neurol Sci, 205, 59, 10.1016/S0022-510X(02)00313-1

Tugnoli, 2007, Botulinum toxin type A reduces capsaicin-evoked pain and neurogenic vasodilatation in human skin, Pain, 130, 76, 10.1016/j.pain.2006.10.030

Sycha, 2006, A lack of antinociceptive or antiinflammatory effect of botulinum toxin A in an inflammatory human pain model, Anesth Analg, 102, 509, 10.1213/01.ane.0000194447.46763.73

Gazerani, 2009, Subcutaneous botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin, Pain, 141, 60, 10.1016/j.pain.2008.10.005

Gazerani, 2006, The effects of botulinum toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization, Pain, 122, 315, 10.1016/j.pain.2006.04.014

Ambache, 1951, A further survey of the action of Clostridium botulinum toxin upon different types of autonomic nerve fibre, J Physiol (Lond), 113, 1, 10.1113/jphysiol.1951.sp004551

Sycha, 2003, A simple pain model for the evaluation of analgesic effects of NSAIDs in healthy subjects, Br J Clin Pharmacol, 56, 165, 10.1046/j.0306-5251.2003.01869.x

Gustorff, 2004, The sunburn pain model: the stability of primary and secondary hyperalgesia over 10 hours in a crossover setting, Anesth Analg, 98, 173, 10.1213/01.ANE.0000093224.77281.A5

Gustorff, 2004, The effects of remifentanil and gabapentin on hyperalgesia in a new extended inflammatory skin pain model in healthy volunteers, Anesth Analg, 98, 401, 10.1213/01.ANE.0000095150.76735.5D

Sycha, 2005, Rofecoxib attenuates both primary and secondary inflammatory hyperalgesia: a randomized, double blinded, placebo controlled crossover trial in the UV-B pain model, Pain, 113, 316, 10.1016/j.pain.2004.11.002

Kaube, 2000, A new method to increase nociception specificity of the human blink reflex, Clin Neurophysiol, 111, 413, 10.1016/S1388-2457(99)00295-3

Lalli, 2003, The journey of tetanus and botulinum neurotoxins in neurons, Trends Microbiol, 11, 431, 10.1016/S0966-842X(03)00210-5

Antonucci, 2008, Long-distance retrograde effects of botulinum neurotoxin A, J Neurosci, 28, 3689, 10.1523/JNEUROSCI.0375-08.2008

Caleo, 2009, A reappraisal of the central effects of botulinum neurotoxin type A: by what mechanism?, J Neurochem, 109, 15, 10.1111/j.1471-4159.2009.05887.x

Caleo, 2009, Central effects of tetanus and botulinum neurotoxins, Toxicon, 54, 593, 10.1016/j.toxicon.2008.12.026

Bozzi, 2006, Action of botulinum neurotoxins in the central nervous system: antiepileptic effects, Neurotox Res, 9, 197, 10.1007/BF03033939

Aoki, 2008, Allergan. Is botulinum toxin really moving into the CNS like tetanus toxin?, J Neurosci

Curra, 2009, Do the unintended actions of botulinum toxin at distant sites have clinical implications?, Neurology, 72, 1095, 10.1212/01.wnl.0000345010.98495.fc